FDA considers limiting authorisation of certain monoclonal antibody treatments

CNN

23 January 2022 - Federal regulators are considering limiting the authorisation of certain monoclonal antibody treatments that have not proved effective against the Omicron variant of the coronavirus, a source familiar with the decision-making told CNN.

The US FDA could decide in the coming days to take steps to curb the use of antibody treatments produced by Eli Lilly and Regeneron, the source said, pointing to the growing body of evidence that shows their monoclonal therapies don't effectively neutralize the virus' Omicron variant.

Read CNN article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Regulation , COVID-19